4592.T

SanBio Company Limited [4592.T] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

4592.T Stock Summary

Top 10 Correlated ETFs

4592.T

Top 10 Correlated Stocks

4592.T

In the News

4592.T Financial details

Company Rating
-
Market Cap
28.89B
Income
-2.64B
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
65
Optionable
No
Shortable
Yes
Earnings
12 Jun 2024
P/E
-5.25
Forward P/E
-
PEG
0.91
P/S
-
P/B
15.89
P/C
-
P/FCF
-
Quick Ratio
3.96
Current Ratio
4.36
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-40.52
EPS next Y
-
EPS next Q
-
EPS this Y
-57.83%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-16.7%
Revenue last 5Y
-100%
Revenue Q/Q
-
EPS Q/Q
686.99%
-
-
-
-
SMA20
35.04%
SMA50
117.59%
SMA100
121.83%
Inst Own
-
Inst Trans
-
ROA
-132%
ROE
-184%
ROC
-1.56%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
380.0-910.0
52W High
+154.4%
52W Low
+509.21%
RSI
64.83
Rel Volume
4.61
Avg Volume
1.74M
Volume
8.01M
Perf Week
1.62%
Perf Month
78.49%
Perf Quarter
129.21%
Perf Half Y
127.85%
-
-
-
-
Beta
0.572
-
-
Volatility
140.63%, 320.23%
Prev Close
15.92%
Price
2315
Change
13.2%

Something similar

Top by Market Cap
ABEC.DE
VFINX
APC.DE
CMC.DE
DHR-PB
Top Correlated ETFs
GOAU
SGDM
GLD
IAU
OUNZ
Top Correlated Stocks
RGLD
OGC.TO
EGO
SAND
3034.T
Similar Market Cap
SHAKTIPUMP.NS
FSUGY
0HW4.L
TCPLPACK.NS
9739.T

Company Profile

Healthcare Biotechnology
  • Volume Average 1.74M
  • Market Capitalization 28.89B
  • Employee 65
  • CEO Mr. Keita Mori MBA
  • Headquarters Tokyo,JP
  • IPO Date 2015-04-08
  • Website https://www.sanbio.jp

SanBio Company Limited develops, produces, and sells regenerative cell medicines for the central nervous system. The company develops SB623 that has completed a phase 2 clinical trial to treat traumatic brain injury in the United States and Japan. Its research pipeline products also comprise SB623 for ischemic and hemorrhagic strokes, age-related macular degeneration, retinitis pigments, spinal cord injury, Parkinson's disease, Alzheimer's disease, and others; SB618 for peripheral nerve damage; SB308 for muscular dystrophy disease; MSC1 for cancer; and MSC2 for inflammatory disease and optic neuritis. The company was founded in 2001 and is headquartered in Tokyo, Japan.